Last updated: July 23, 2026
Executive summary: No. 2:22-cv-06104 is a patent litigation matter between Adverio Pharma GmbH (plaintiff) and Alembic Pharmaceutical Limited (defendant). The case number indicates a federal action filed in U.S. District Court in 2022. A litigation summary and infringement/validity posture analysis requires the underlying complaint, asserted patent numbers, ANDA/Biologics license application references, claim chart or allegations, and the docket’s key events (motions to dismiss, Markman, preliminary injunction, claim construction schedule, settlement dates). Those case-specific details are not included in the prompt, so a complete and accurate litigation summary cannot be produced.
What is ADVERIO PHARMA GMBH v. ALEMBIC PHARMACEUTICAL LIMITED (2:22-cv-06104) about?
Featured snippet answer: A U.S. federal patent case filed in 2022 alleging infringement by Alembic against Adverio. Specific asserted patents, the drug/product at issue, and the legal theories (ANDA Paragraph IV, 35 U.S.C. § 271(a)/(b)/(c), inducement, contributory infringement) are not provided.
What patents were asserted?
A full litigation analysis depends on:
- Patent numbers and publication/publication history
- Patent owner(s) and assignee(s)
- Whether the suit asserts product, method-of-use, formulation, polymorph/crystal form, or manufacturing method claims
No asserted-patent identifiers are provided for 2:22-cv-06104 in the input.
What regulatory mechanism triggered the suit?
Patent suits in the generic space are typically tied to:
- An ANDA with Paragraph IV certifications (35 U.S.C. § 355(j)(2)(A)(vii) or (viii))
- A counterclaim seeking invalidity/non-infringement
- A request for injunction tied to the statutory 30-month stay
The prompt does not include the ANDA/Paragraph IV details or the FDA applicant/product formulation.
What procedural posture does 2:22-cv-06104 reflect?
Featured snippet answer: Procedural posture (e.g., initial complaint, amended complaint, answer, motion practice, Markman, summary judgment, trial, settlement) cannot be determined from the case number alone.
Key docket events that drive analysis
A litigation investment or licensing decision turns on:
- Whether there was a preliminary injunction motion and outcome
- Whether the court stayed proceedings under customary claim construction timelines
- Whether defendants filed a motion to dismiss for failure to state a claim
- Whether the case resolved by settlement, consent judgment, or dismissal with prejudice
No docket events are included in the input.
How do courts typically analyze the asserted claims in ADVERIO vs ALEMBIC-style ANDA litigation?
Featured snippet answer: Typical analysis in Paragraph IV cases is claim construction first, then infringement and invalidity on the construed claims. The exact framework depends on the asserted claim types and the defendant’s accused product.
Infringement themes to expect (and what must be cited)
Common patterns include:
- Literal infringement based on identical active ingredient(s), dose, salt form, polymorph, and release profile
- Doctrine of equivalents for formulation/process differences
- Method-of-use infringement for dosing regimens or patient populations
Claim-specific allegations are missing from the prompt, so the case-specific themes cannot be stated.
Invalidity themes to expect (and what must be cited)
Typical defenses include:
- Anticipation/obviousness under §§ 102/103
- Lack of enablement or written description under § 112
- Obviousness-type double patenting for continuation/terminal disclaimer issues
- Indefiniteness under § 112(b)
No asserted patent details are provided, so invalidity analysis cannot be grounded to this case.
What claim and product details matter for a generic entry risk assessment?
Featured snippet answer: Entry risk depends on the specific drug product, the accused formulation, the FDA application number, and the remaining exclusivity and patent term. Those data are not included for 2:22-cv-06104.
What must be known to model “generic launch” outcomes
- Patent expiration dates for each asserted patent
- Whether the court found non-infringement or invalidity
- Whether an injunction issued and how it scope-limits the “skinny label” or workaround
- Whether settlement triggers an agreed “design-around” or delayed launch date
None of those case-specific data points are provided.
What is the Paragraph IV and Orange Book alignment for this dispute?
Featured snippet answer: The Orange Book status, the specific patents listed for the relevant NDA/Reference Product, and the Paragraph IV certification basis cannot be verified from the prompt.
Orange Book inputs required for validity/infringement context
- Listed patents (drug substance, drug product, methods of use)
- Patent-expiration and exclusivity dates (NCE, 5-year, 7-year, pediatric exclusivity)
- Whether listed patents map to the complaint’s asserted claims
No Orange Book identifiers are included.
How does Alembic’s litigation posture typically map to outcomes?
Featured snippet answer: Alembic’s posture can include non-infringement, invalidity, and carve-outs tied to design-around positions, but the case-specific filings are not provided.
Settlement vs. adjudication decision points
In generic patent cases, outcomes typically split between:
- Settlement with payment/delay terms (and sometimes license)
- Final judgment on injunction and continued licensing rights
Without docket and settlement terms, no outcome analysis can be stated.
Key takesaways
- Case identity confirmed: ADVERIO PHARMA GMBH v. ALEMBIC PHARMACEUTICAL LIMITED, No. 2:22-cv-06104.
- Insufficient inputs: The prompt lacks asserted patent numbers, accused product/ANDA details, and docket outcomes, which are necessary for a complete litigation summary and business-relevant legal analysis.
FAQs
1) What is the court location for 2:22-cv-06104?
Not provided.
2) Which patents are asserted by Adverio in 2:22-cv-06104?
Not provided.
3) Does 2:22-cv-06104 involve an ANDA Paragraph IV certification?
Not provided.
4) What is the status of the case (pending, settled, dismissed, or judgment entered)?
Not provided.
5) What generic entry date risk applies to Alembic’s product?
Not provided.
References
- Not available from the provided input.
